Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

Publication ,  Journal Article
Khasraw, M; Bell, R
Published in: Expert Rev Anticancer Ther
August 2012

Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and after systemic therapy. Trastuzumab is a monoclonal antibody targeting the hEGF receptor that is overexpressed in 15-20% of breast tumors. Trastuzumab is effective in prolonging survival when used to treat women with hEGF receptor overexpressed tumors, both in adjuvant and metastatic disease settings. Trastuzumab has also shown promising activity in PST/neoadjuvant studies by achieving high rates of complete pathologic response. This is a review of clinical studies that incorporated trastuzumab in PST and/or neoadjuvant chemotherapy, including the results of recently reported studies using trastuzumab in combination with other novel therapies such as lapatinib or pertuzumab.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

August 2012

Volume

12

Issue

8

Start / End Page

1005 / 1013

Location

England

Related Subject Headings

  • Trastuzumab
  • Taxoids
  • Sulfonamides
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Randomized Controlled Trials as Topic
  • Quinazolines
  • Pyrazoles
  • Paclitaxel
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khasraw, M., & Bell, R. (2012). Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev Anticancer Ther, 12(8), 1005–1013. https://doi.org/10.1586/era.12.62
Khasraw, Mustafa, and Richard Bell. “Primary systemic therapy in HER2-amplified breast cancer: a clinical review.Expert Rev Anticancer Ther 12, no. 8 (August 2012): 1005–13. https://doi.org/10.1586/era.12.62.
Khasraw M, Bell R. Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev Anticancer Ther. 2012 Aug;12(8):1005–13.
Khasraw, Mustafa, and Richard Bell. “Primary systemic therapy in HER2-amplified breast cancer: a clinical review.Expert Rev Anticancer Ther, vol. 12, no. 8, Aug. 2012, pp. 1005–13. Pubmed, doi:10.1586/era.12.62.
Khasraw M, Bell R. Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert Rev Anticancer Ther. 2012 Aug;12(8):1005–1013.
Journal cover image

Published In

Expert Rev Anticancer Ther

DOI

EISSN

1744-8328

Publication Date

August 2012

Volume

12

Issue

8

Start / End Page

1005 / 1013

Location

England

Related Subject Headings

  • Trastuzumab
  • Taxoids
  • Sulfonamides
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Randomized Controlled Trials as Topic
  • Quinazolines
  • Pyrazoles
  • Paclitaxel
  • Oncology & Carcinogenesis